^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD5-targeted CAR-T immunotherapy

    Related drugs:
    Associations

    News

    Trials
    26d
    CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors (clinicaltrials.gov)
    P=N/A, N=18, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial
    1m
    VIPER-101: CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov)
    P1, N=30, Recruiting, Vittoria Biotherapeutics | Trial completion date: Jun 2027 --> Aug 2029 | Trial primary completion date: Aug 2026 --> Aug 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    cyclophosphamide
    3ms
    MAGENTA: Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (clinicaltrials.gov)
    P1, N=54, Recruiting, Baylor College of Medicine | Trial primary completion date: Jan 2026 --> Jun 2028
    Trial primary completion date
    |
    CD5 (CD5 Molecule)
    |
    cyclophosphamide • MB-105
    5ms
    A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies (clinicaltrials.gov)
    P1/2, N=54, Recruiting, Beijing GoBroad Hospital
    New P1/2 trial
    6ms
    CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas (clinicaltrials.gov)
    P1/2, N=36, Recruiting, Beijing GoBroad Hospital
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    9ms
    Phase I/II: Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Peking University People's Hospital
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    11ms
    MB-105 in Patients With CD5 Positive T-cell Lymphoma (clinicaltrials.gov)
    P2, N=46, Recruiting, March Biosciences Inc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MB-105
    1year
    Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=19, Terminated, Beijing Boren Hospital | Recruiting --> Terminated; ethic commitee decision
    Trial termination
    |
    CD5 (CD5 Molecule)
    |
    CD5 positive
    |
    cyclophosphamide
    1year
    Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)
    P1, N=0, Withdrawn, Beijing Boren Hospital | N=18 --> 0 | Trial completion date: Jul 2024 --> Dec 2023 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2024 --> Dec 2023
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    CD5 (CD5 Molecule)
    |
    CD5 positive
    |
    cyclophosphamide • CD5 CAR T (CT125B)
    1year
    Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL (clinicaltrials.gov)
    P1, N=30, Recruiting, Zhejiang University
    New P1 trial
    1year
    Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Zhejiang University
    New P1 trial • CAR T-Cell Therapy
    1year
    Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial. (PubMed, Nat Med)
    This study provides insights that could help to optimize this promising intervention. ClinicalTrials.gov registration: NCT05032599 .
    P1 data • Journal
    |
    CD5 (CD5 Molecule) • CD7 (CD7 Molecule)